A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases
Artikel i vetenskaplig tidskrift, 2026
Cardiovascular diseases (CVD) remain a major global health challenge. Early markers of disease initiation and progression are urgently needed. We, and others, have previously shown changes in the gut microbiome in association with metabolic and CVD. Here, we demonstrate that gut microbiome-related changes can be detected in association with subclinical variations in heart and kidney function. Markers related to gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate in a metabolically healthy European population. Observational and genetic evidence further identify microbiome-related metabolites as mediators of this gut microbiome-kidney axis, with their baseline levels associating with incident CVD in an external Canadian population. Altogether, our work suggests that the gut microbiome interacts with the cardiorenal axis and participates in an interorgan crosstalk affecting host physiology and risk of CVD.
Författare
Kanta Chechi
Department of Metabolism
National Heart and Lung Institute
Rima Chakaroun
Wallenberg Lab.
Universität Leipzig
Antonis Myridakis
Department of Metabolism
Sofia K. Forslund
Max Delbrueck Centrum Fuer Molekulare Medizin
Deutsches Zentrum für Herz-Kreislauf-Forschung e. V.
Charité Universitätsmedizin Berlin
Sebastien Fromentin
Université Paris-Saclay
Trine Nielsen
Sjællands Universitetshospital
Steno Diabetes Center
Köpenhamns universitet
Novo Nordisk Fonden
Judith Aron-Wisneswky
Université Pierre et Marie Curie (UPMC)
Assistance publique – Hôpitaux de Paris (AP-HP)
Eugeni Belda
Université Pierre et Marie Curie (UPMC)
Edi Prifti
Université Pierre et Marie Curie (UPMC)
Pierre Bel-Lassen
Université Pierre et Marie Curie (UPMC)
Assistance publique – Hôpitaux de Paris (AP-HP)
Gwen Falony
KU Leuven
Flanders Interuniversity Institute for Biotechnology
University Medical Center Mainz
Wageningen University and Research
Sara Vieira-Silva
KU Leuven
University Medical Center Mainz
Flanders Interuniversity Institute for Biotechnology
Universite catholique de Louvain
J. Chilloux
Department of Metabolism
Kazuhiro Sonomura
Shimadzu Corporation
L. Hoyles
Nottingham Trent University
Department of Metabolism
Laura Martinez-Gili
Department of Metabolism
Francesco Pallotti
Università degli Studi di Enna “Kore”
Department of Metabolism
Petros Andrikopoulos
Department of Metabolism
Francesc Puig-Castellvi
CHU Lille
Romina Pacheco Tapia
CHU Lille
Inés Castro-Dionicio
CHU Lille
Hugo Roume
Université Paris-Saclay
Nicolas Pons
Université Paris-Saclay
Emmanuelle Le Chatelier
Université Paris-Saclay
Benoit Quinquis
Université Paris-Saclay
Nathalie Galleron
Université Paris-Saclay
Magali Berland
Université Paris-Saclay
Michael Olanipekun
Department of Metabolism
Manyi Jia
Department of Metabolism
Angelos Manolias
Department of Metabolism
Bridget Holmes
Danone Research
Food and Agriculture Organization of the United Nations
Solia Adriouch
Université Pierre et Marie Curie (UPMC)
M. Bluher
Universität Leipzig
Luis P. Coelho
European Molecular Biology Laboratory
Kévin Da Silva
Université Paris-Saclay
Pilar Galan
Inserm Transfert
Boyang Ji
BioInnovation Institute
Chalmers, Life sciences, Systembiologi
Ana Luisa Neves
Imperial College London
Department of Metabolism
Christine Rouault
Université Pierre et Marie Curie (UPMC)
Joe-Elie Salem
Assistance publique – Hôpitaux de Paris (AP-HP)
Valentina Tremaroli
Wallenberg Lab.
Tue H. Hansen
Köpenhamns universitet
Sjællands Universitetshospital
Novo Nordisk Fonden
Nadja B. Søndertoft
Novo Nordisk Fonden
Christian Lewinter
Novo Nordisk Fonden
Helle K. Pedersen
Novo Nordisk Fonden
Peter D. Mark
Rigshospitalet
Jens P. Goetze
Rigshospitalet
Lars Køber
Köpenhamns universitet
Rigshospitalet
H. Vestergaard
Novo Nordisk Fonden
Steno Diabetes Center
Torben Hansen
Novo Nordisk Fonden
Syddansk Universitet
Jean-Daniel Zucker
Université Pierre et Marie Curie (UPMC)
Taka Aki Sato
Shimadzu Corporation
Serge Hercberg
Inserm Transfert
Fredrik Bäckhed
Wallenberg Lab.
Sahlgrenska universitetssjukhuset
Ivica Letunic
Universität Heidelberg
Biobyte Solutions
Jean-Michel Oppert
Assistance publique – Hôpitaux de Paris (AP-HP)
Jens B Nielsen
Chalmers, Life sciences, Systembiologi
BioInnovation Institute
Jeroen Raes
KU Leuven
Flanders Interuniversity Institute for Biotechnology
Ioanna Tzoulaki
Academy of Athens
Imperial College London
Department of Metabolism
Abbas Dehghan
Department of Metabolism
Imperial College London
Verena Zuber
Department of Metabolism
Imperial College London
MRC Centre for Environment and Health
Emmanuelle Bouzigon
Inserm Transfert
Mark Lathrop
McGill University
Parminder Raina
McMaster University
Philippe Froguel
CHU Lille
Imperial College London
Fumihiko Matsuda
Kyoto University
Florence Demenais
Inserm Transfert
Dominique Gauguier
McGill University
Centre national de la recherche scientifique (CNRS)
Kyoto University
M. Stumvoll
Universität Leipzig
Peer Bork
Max Delbrueck Centrum Fuer Molekulare Medizin
Universität Heidelberg
European Molecular Biology Laboratory
O. B. Pedersen
Köpenhamns universitet
Gentofte Hospital
Novo Nordisk Fonden
Stanislav Dusko Ehrlich
Université Paris-Saclay
University College London (UCL)
K. Clement
Assistance publique – Hôpitaux de Paris (AP-HP)
Université Pierre et Marie Curie (UPMC)
Marc-Emmanuel Dumas
Department of Metabolism
McGill University
National Heart and Lung Institute
CHU Lille
Nature Communications
2041-1723 (ISSN) 20411723 (eISSN)
Vol. 17 1Ämneskategorier (SSIF 2025)
Mikrobiologi inom det medicinska området
Kardiologi och kardiovaskulära sjukdomar
Endokrinologi och diabetes
DOI
10.1038/s41467-026-69405-0
PubMed
41786749